Show simple item record

dc.contributor.authorParry, Marina
dc.contributor.authorSrivastava, Shambhavi
dc.contributor.authorAli, Adnan
dc.contributor.authorCannistraci, Alession
dc.contributor.authorAntonello, Jenny
dc.contributor.authorBarros-Silva, Joao D
dc.contributor.authorUbertini, Valentina
dc.contributor.authorRamani, Vijay A C
dc.contributor.authorLau, Maurice W
dc.contributor.authorShanks, Jonathan H
dc.contributor.authorNonaka, Daisuke
dc.contributor.authorOliveira, Pedro
dc.contributor.authorHambrock, Thomas
dc.contributor.authorLeong, Hui Sun
dc.contributor.authorDhomen, Nathalie
dc.contributor.authorMiller, Crispin J
dc.contributor.authorBrady, Ged
dc.contributor.authorDive, Caroline
dc.contributor.authorClarke, Noel W
dc.contributor.authorMarais, Richard
dc.contributor.authorBaena, Esther
dc.date.accessioned2019-04-29T09:48:55Z
dc.date.available2019-04-29T09:48:55Z
dc.date.issued2019en
dc.identifier.citationParry MA, Srivastava S, Ali A, Cannistraci A, Antonello J, Barros-Silva JD, et al. Genomic evaluation of multiparametric magnetic resonance imaging-visible and -nonvisible lesions in clinically localised prostate cancer Cancer. Eur Urol Oncol. 2019 Feb;2(1):1-11.en
dc.identifier.pmid30929837en
dc.identifier.doi10.1016/j.euo.2018.08.005en
dc.identifier.urihttp://hdl.handle.net/10541/621748
dc.description.abstractBACKGROUND: The prostate cancer (PCa) diagnostic pathway is undergoing a radical change with the introduction of multiparametric magnetic resonance imaging (mpMRI), genomic testing, and different prostate biopsy techniques. It has been proposed that these tests should be used in a sequential manner to optimise risk stratification. OBJECTIVE: To characterise the genomic, epigenomic, and transcriptomic features of mpMRI-visible and -nonvisible PCa in clinically localised disease. DESIGN, SETTING, AND PARTICIPANTS: Multicore analysis of fresh prostate tissue sampled immediately after radical prostatectomy was performed for intermediate- to high-risk PCa. INTERVENTION: Low-pass whole-genome, exome, methylation, and transcriptome profiling of patient tissue cores taken from microscopically benign and cancerous areas in the same prostate. Circulating free and germline DNA was assessed from the blood of five patients. OUTCOME MEASUREMENT AND STATISTICAL ANALYSIS: Correlations between preoperative mpMRI and genomic characteristics of tumour and benign prostate samples were assessed. Gene profiles for individual tumour cores were correlated with existing genomic classifiers currently used for prognostication. RESULTS AND LIMITATIONS: A total of 43 prostate cores (22 tumour and 21 benign) were profiled from six whole prostate glands. Of the 22 tumour cores, 16 were tumours visible and six were tumours nonvisible on mpMRI. Intratumour genomic, epigenomic, and transcriptomic heterogeneity was found within mpMRI-visible lesions. This could potentially lead to misclassification of patients using signatures based on copy number or RNA expression. Moreover, three of the six cores obtained from mpMRI-nonvisible tumours harboured one or more genetic alterations commonly observed in metastatic castration-resistant PCa. No circulating free DNA alterations were found. Limitations include the small cohort size and lack of follow-up. CONCLUSIONS: Our study supports the continued use of systematic prostate sampling in addition to mpMRI, as avoidance of systematic biopsies in patients with negative mpMRI may mean that clinically significant tumours harbouring genetic alterations commonly seen in metastatic PCa are missed. Furthermore, there is inconsistency in individual genomics when genomic classifiers are applied. PATIENT SUMMARY: Our study shows that tumour heterogeneity within prostate tumours visible on multiparametric magnetic resonance imaging (mpMRI) can lead to misclassification of patients if only one core is used for genomic analysis. In addition, some cancers that were missed by mpMRI had genomic aberrations that are commonly seen in advanced metastatic prostate cancer. Avoiding biopsies in mpMRI-negative cases may mean that such potentially lethal cancers are missed.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.euo.2018.08.005en
dc.titleGenomic evaluation of multiparametric magnetic resonance imaging-visible and -nonvisible lesions in clinically localised prostate canceren
dc.typeArticleen
dc.contributor.departmentMolecular Oncology, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UKen
dc.identifier.journalEuropean Urology Oncologyen
dc.description.noteen]
refterms.dateFOA2019-04-29T16:54:36Z


Files in this item

Thumbnail
Name:
genomic-main.pdf
Size:
3.038Mb
Format:
PDF
Description:
Open Access, Full Text Article

This item appears in the following Collection(s)

Show simple item record